These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 14371762)

  • 1. [Special licenses concerning patents for the production of pharmaceuticals and the method of transferring patents].
    MARTELLIERE E
    Prod Pharm; 1955 Jan; 10(1):50-2. PubMed ID: 14371762
    [No Abstract]   [Full Text] [Related]  

  • 2. [Compulsory licenses and the assignment of patents].
    MARTELLIERE E
    Prod Pharm; 1954 Oct; 9(10):595-9. PubMed ID: 13215579
    [No Abstract]   [Full Text] [Related]  

  • 3. [Permits for patent medicines and the right of transferring them].
    MARTELLIERE E
    Prod Pharm; 1961 Jan; 16():28-9. PubMed ID: 13767279
    [No Abstract]   [Full Text] [Related]  

  • 4. [Pharmacy in Norway].
    Karlsen J
    Pharm Weekbl; 1967 Aug; 102(31):771-4. PubMed ID: 5591081
    [No Abstract]   [Full Text] [Related]  

  • 5. [Patent rights in pharmacy].
    Madeuf MC
    Farmaco Prat; 1968 May; 23(5):227-37. PubMed ID: 5712398
    [No Abstract]   [Full Text] [Related]  

  • 6. [Proposed new law on pharmacy].
    Ugeskr Laeger; 1953 Nov; 115(47):1745-6. PubMed ID: 13136545
    [No Abstract]   [Full Text] [Related]  

  • 7. [The "third party" in the pharmaceutical industry].
    Karrer E
    Boll Chim Farm; 1966 Aug; 105(8):563-9. PubMed ID: 6003361
    [No Abstract]   [Full Text] [Related]  

  • 8. [Quality control in pharmaceutic industry].
    de Oliveira E
    Hospital (Rio J); 1969 Feb; 75(2):543-61. PubMed ID: 5311212
    [No Abstract]   [Full Text] [Related]  

  • 9. Considerations for developing an antiarrhythmic agent: a perspective from the pharmaceutical industry.
    Antonaccio MJ
    Can J Cardiol; 1994 Apr; 10(3):325-6. PubMed ID: 8162528
    [No Abstract]   [Full Text] [Related]  

  • 10. [The responsibility of the pharmaceutical industry].
    Andersen K
    Nord Med; 1975 Apr; 90(4):115. PubMed ID: 1134911
    [No Abstract]   [Full Text] [Related]  

  • 11. [Some aspects of pharmaceutical control in Europe].
    Scowen EF
    Cah Med; 1973 Apr; 14(4):307-9. PubMed ID: 4742880
    [No Abstract]   [Full Text] [Related]  

  • 12. Brand names.
    Br Med J; 1968 Mar; 1(5595):781-2. PubMed ID: 5641479
    [No Abstract]   [Full Text] [Related]  

  • 13. Sainsbury Report.
    Br Med J; 1967 Oct; 4(5570):1-2. PubMed ID: 6047821
    [No Abstract]   [Full Text] [Related]  

  • 14. Bill 102: deal or no deal for big pharma.
    Rasky H
    Health Law Can; 2007 May; 27(4):73-84. PubMed ID: 17580795
    [No Abstract]   [Full Text] [Related]  

  • 15. The role of government as it affects the pharmaceutical industry and profession.
    HOLLAND AH
    Am J Pharm Sci Support Public Health; 1955 May; 127(5):158-63. PubMed ID: 13354727
    [No Abstract]   [Full Text] [Related]  

  • 16. When consumers are patents.
    Can Med Assoc J; 1969 Feb; 100(6):301-2. PubMed ID: 5764288
    [No Abstract]   [Full Text] [Related]  

  • 17. Ownership of knowledge--the role of patents in pharmaceutical R&D.
    Correa CM
    Bull World Health Organ; 2004 Oct; 82(10):784-7; discussion 787-90. PubMed ID: 15643801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reach-through claims for drug target patents: Rx for pharmaceutical policy.
    Bohrer RA
    Nat Biotechnol; 2008 Jan; 26(1):55-6. PubMed ID: 18183015
    [No Abstract]   [Full Text] [Related]  

  • 19. [Reform plans for pharmaceutical legislation: permit for drugs & drug patents].
    MARTELLIERE E
    Prod Pharm; 1959 Apr; 14(4):213-9 concl. PubMed ID: 13645809
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacies receiving massive rebates from generic drug-makers.
    Silversides A
    CMAJ; 2006 Aug; 175(4):342. PubMed ID: 16908889
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.